Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

TELIX Pharmaceuticals Ltd

Healthcare AU TLX

14.56AUD
0.35(2.46%)

Last update at 2026-06-23T06:10:00Z

Day Range

14.2714.93
LowHigh

52 Week Range

8.2625.87
LowHigh

Fundamentals

  • Previous Close 14.21
  • Market Cap4851.29M
  • Volume1870789
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA32.46M
  • Revenue TTM803.79M
  • Revenue Per Share TTM2.38
  • Gross Profit TTM 381.84M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.16670M 56.06M 3.09M -98.62200M -80.46500M
Minority interest - - - - -
Net income -11.04970M 49.92M 5.21M -104.07900M -80.51000M
Selling general administrative 192.56M 117.66M 78.98M 77.32M 34.92M
Selling and marketing expenses - 115.20M 54.87M 16.19M 5.89M
Gross profit 662.07M 509.68M 314.39M 94.43M 2.35M
Reconciled depreciation - - 6.74M 5.38M 5.17M
Ebit 27.55M 86.86M 16.22M -92.20600M -75.24700M
Ebitda 61.33M 92.55M 22.97M -86.82700M -70.07300M
Depreciation and amortization 33.78M 5.69M 6.74M 5.38M 5.17M
Non operating income net other - - - - -
Operating income 27.55M 82.13M 51.89M -92.20600M -75.24700M
Other operating expenses 1219.00M 701.08M 451.03M 251.00M 103.70M
Interest expense 56.94M 21.46M 1.00M 6.42M 5.22M
Tax provision 1.86M 6.14M -2.12400M 5.46M 0.04M
Interest income 7.94M 10.86M 1.02M 0.00100M 0.16M
Net interest income - -26.07400M -12.75300M -6.69200M -5.21800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.88M 6.14M -2.12400M 5.46M 0.04M
Total revenue 1246.55M 783.21M 502.55M 155.98M 4.90M
Total operating expenses 634.52M 427.55M 263.27M 189.44M 101.15M
Cost of revenue 584.48M 273.53M 188.16M 61.56M 2.55M
Total other income expense net -35.71728M -26.07400M -48.80000M -6.41600M -5.21800M
Discontinued operations - - - - -
Net income from continuing ops - 49.92M 5.21M -104.07900M -80.51000M
Net income applicable to common shares -7.12500M 49.92M 5.21M -104.07900M -80.51000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1772.67M 1516.43M 398.30M 255.35M 109.81M
Intangible assets 590.59M 309.49M 104.82M 53.47M 51.63M
Earning assets - - - - -
Other current assets 19.44M - 7.10M 6.57M 1.43M
Total liab 1149.78M 948.22M 249.39M 175.35M 107.66M
Total stockholder equity 622.89M 568.21M 148.91M 80.01M 2.16M
Deferred long term liab - - - - -
Other current liab 194.70M 85.91M 123.01M 68.11M 6.14M
Common stock 719.75M - 446.27M 370.97M 170.84M
Capital stock - 0.00000M 446.27M 370.97M 170.84M
Retained earnings -231.74327M -212.96200M -263.66500M -272.81500M -173.47100M
Other liab - - - 79.98M 67.77M
Good will 298.40M 106.65M 4.85M 5.52M 4.10M
Other assets 120.25M - - 3.97M 0.21M
Cash 212.74M 710.35M 123.24M 116.33M 22.04M
Cash and equivalents - - - - -
Total current liabilities 347.34M 330.91M 157.41M 85.56M 37.98M
Current deferred revenue 17.20M - 112.02M - 19.32M
Net debt 572.50M - -105.79200M -105.88300M -19.49800M
Short term debt 27.98M - 1.56M 0.64M 0.63M
Short long term debt - 18.99M 0.96M - 0.02M
Short long term debt total 785.24M - 17.45M 10.45M 2.54M
Other stockholder equity -7.36800M - - -0.56200M 4.79M
Property plant equipment 115.61M - - 18.84M 6.33M
Total current assets 495.28M 918.56M 224.85M 173.23M 47.54M
Long term investments - 6.09M 12.26M - -
Net tangible assets - - - 21.02M -53.57100M
Short term investments - - - - -
Net receivables 207.50M 139.44M 64.78M 39.35M 19.42M
Long term debt 391.91M 551.82M 8.21M 3.31M 0.00000M
Inventory 55.60M 38.14M 17.31M 8.48M 3.45M
Accounts payable 107.46M 68.70M 32.84M 16.81M 11.88M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 134.89M - -33.69200M -18.15000M 4.79M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 43.23M 74.58M 1.17M 0.33M 0.21M
Deferred long term asset charges - - - - -
Non current assets total 1277.39M 597.87M 173.45M 82.12M 62.27M
Capital lease obligations - 10.64M 8.27M 7.13M 2.52M
Long term debt total 448.45M - - 9.80M 1.91M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -135.17300M -25.48900M -16.99700M -2.72600M
Change to liabilities - - - 27.64M 4.79M
Total cashflows from investing activities -443.41634M -135.17300M -25.48900M -16.99700M -2.72600M
Net borrowings - 405.93M 2.41M 1.74M -0.93600M
Total cash from financing activities -5.76755M 638.92M 10.19M 174.96M 2.85M
Change to operating activities - - - -3.68600M 2.60M
Net income -11.04970M 49.92M 5.21M -104.07900M -80.51000M
Change in cash -497.60550M 587.11M 6.91M 94.29M -55.90800M
Begin period cash flow 710.35M 123.24M 116.33M 22.04M 77.94M
End period cash flow 212.74M 710.35M 123.24M 116.33M 22.04M
Total cash from operating activities -26.81859M 43.03M 23.88M -63.97000M -59.32800M
Issuance of capital stock - 1.00M 6.65M 181.04M 3.78M
Depreciation 33.78M - 6.92M 5.38M 5.17M
Other cashflows from investing activities -12.97584M -34.16900M -1.17100M -2.16300M -1.38700M
Dividends paid - - - 168.41M -
Change to inventory -11.84683M -3.23900M -9.63600M -5.02300M -2.82100M
Change to account receivables -31.73784M -57.08000M -27.38200M -19.93400M -7.19200M
Sale purchase of stock 1.81M 1.00M 6.65M -7.81600M 3.78M
Other cashflows from financing activities -8.12172M -14.88400M -2.22200M -1.26400M -0.59600M
Change to netincome - - - 35.74M 18.64M
Capital expenditures 58.80M 34.03M 10.79M 13.86M 1.34M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -70.12256M -64.27100M -57.53400M -1.00700M -2.63000M
Stock based compensation - - 8.79M 8.11M 1.32M
Other non cash items 20.57M 107.30M 60.50M 41.00M 31.52M
Free cash flow -85.62006M 9.00M 13.09M -77.83100M -60.66700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TLX
TELIX Pharmaceuticals Ltd		 0.35 2.46% 14.56 - 2000.00 6.04 8.25 4.67 106.76
CSL
CSL Ltd		 -0.84 0.74% 112.04 12.39 11.79 3.36 1.94 2.99 8.99
MSB
Mesoblast Ltd		 0.01 0.46% 2.17 - 454.55 40.73 3.14 30.21 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.04 0.32% 12.38 57.61 52.08 25.89 4.85 20.81 61.06
PYC
PYC Therapeutics Ltd		 0.04 2.30% 1.56 - 12.00 69.13 8.92 25.02 -8.4071

Reports Covered

Stock Research & News

View All

Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

TELIX Pharmaceuticals Ltd

55 Flemington Road, North Melbourne, VIC, Australia, 3051

Key Executives

Name Title Year Born
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA Co-Founder, Group MD, CEO & Exec. Director 1975
Dr. Andreas Kluge M.D., Ph.D. Chief Medical Advisor & Director NA
Mr. Darren Smith B.Bus., FCPA, M.B.A. Group Chief Financial Officer 1965
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) Chief Scientist NA
Ms. Kyahn Williamson Sr. VP of Corp. Communications & Investor Relations NA
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. Sr. VP of Global Governance, Risk & Compliance NA
Ms. Lena Moran-Adams Gen. Counsel NA
Ms. Amanda Griffin Communications Mang. NA
Mr. Christian Davis VP Sales and Marketing, EMEA NA
Ms. Meredith Crowe Interim Sr. VP of Global People & Culture NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.